Disease-A-Month
Volume 55, Issue 4 , Pages 198-211 , April 2009

Complications of Botulinum Neurotoxin

References 

  1. Adelson RT. Botulinum neurotoxins: fundamentals for the facial plastic surgeon. Am J Otolaryngol. 2007;28(4):260–266
  2. Hackett R, Kam PC. Botulinum toxin: pharmacology and clinical developments: a literature review. Med Chem. 2007;3(4):333–345
  3. American Society of Plastic Surgeons. Procedural statistics trends 2000-2006. http://www.plasticsurgery.org/media/statistics/index.cfmAccessed January 5, 2008
  4. Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2008;115(4):559–565
  5. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17(1):21–25
  6. Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131–133v
  7. Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21
  8. Carruthers J, Carruthers A. Complications of botulinum toxin type A. Facial Plast Surg Clin North Am. 2007;15(1):51–54vi
  9. Bennett JD, Miller TA, Richards RS. The use of Botox in interventional radiology. Tech Vasc Interv Radiol. 2006;9(1):36–39
  10. Truong DD, Jost WH. Botulinum toxin: clinical use. Parkinsonism Relat Disord. 2006;12(6):331–355
  11. Thakker MM, Rubin PA. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin. 2004;44(3):147–163
  12. Harris CP, Alderson K, Nebeker J, et al. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol. 1991;109(3):393–395
  13. Sadick NS, Matarasso SL. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin. 2004;22(2):221–226
  14. Rohrich RJ, Janis JE, Fagien S, et al. The cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;112(5):177S–188Squiz 188S, 192S; discussion 189S-191S (suppl)
  15. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002;18(6):S133–S141(suppl)
  16. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency (German Dystonia Study Group). J Neurol. 1999;246(4):265–274
  17. Naumann M, Albanese A, Heinen F, et al. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol. 2006;13(suppl 4):35–40
  18. Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res. 2006;9(2-3):121–125
  19. De Boulle KL. Botulinum neurotoxin type A in facial aesthetics. Expert Opin Pharmacother. 2007;8(8):1059–1072
  20. Yamauchi PS, Lask G, Lowe NJ. Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J Cosmet Laser Ther. 2004;6(3):145–148
  21. Carruthers J, Fagien S, Matarasso SL. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004;114(6):1S–22S(suppl)
  22. Baumann L, Black L. Botulinum toxin type B (Myobloc). Dermatol Surg. 2003;29(5):496–500discussion 500
  23. Flynn TC, Clark RE. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29(5):519–522discussion 522
  24. Bosniak S, Cantisano-Zilkha M, Purewal BK, et al. Combination therapies in oculofacial rejuvenation. Orbit. 2006;25(4):319–326
  25. Cote TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407–415
  26. Batra RS, Dover JS, Arndt KA. Adverse event reporting for botulinum toxin type A. J Am Acad Dermatol. 2005;53(6):1080–1082
  27. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059–1070
  28. Tugnoli V, Eleopra R, Quatrale R, et al. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol. 2002;147(4):808–809
  29. LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord. 1997;12(6):1064–1067
  30. Ahbib S, Lachapelle JM, Marot L. Sarcoidal granulomas following injections of botulic toxin A (Botox) for corrections of wrinkles. Ann Dermatol Venereol. 2006;133(1):43–45
  31. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001;108(1):208–214discussion 215-7
  32. Ferreira MC, Salles AG, Gimenez R, et al. Complications with the use of botulinum toxin type a in facial rejuvenation: report of 8 cases. Aesthetic Plast Surg. 2004;28(6):441–444
  33. Tan EK, Lo YL, Seah A, et al. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190(1-2):95–97
  34. Latimer PR, Hodgkins PR, Vakalis AN, et al. Necrotising fasciitis as a complication of botulinum toxin injection. Eye. 1998;12(Pt 1):51–53
  35. Agaba AE, Mahmoud S, Esmail H, et al. Extensive myofascial necrosis: a delayed complication of botulinum toxin therapy. Eur J Intern Med. 2005;16(8):603–605
  36. Dayan SH, Maas CS. Botulinum toxins for facial wrinkles: beyond glabellar lines. Facial Plast Surg Clin North Am. 2007;15(1):41–49vi
  37. Frankel AS, Markarian A. Cosmetic treatments and strategies for the upper face. Facial Plast Surg Clin North Am. 2007;15(1):31–39vi
  38. Harth W, Linse R. Botulinophilia: contraindication for therapy with botulinum toxin. Int J Clin Pharmacol Ther. 2001;39(10):460–463

PII: S0011-5029(09)00003-0

doi: 10.1016/j.disamonth.2009.01.001

Disease-A-Month
Volume 55, Issue 4 , Pages 198-211 , April 2009

Article Tools

* Image Usage & Resolution